抄録
Patients with advanced heart failure often accompany severe function mitral regurgitation refractory to optimal medical therapy. Degenerative mitral regurgitation also develops due to various degeneration of mitral valve. Surgical intervention to the mitral valve might be effective in some cases, but it is challenging for the high-risk cases. Recently, percutaneous edge-to-edge mitral valve repair using the MitraClip system, which en-ables us to approach the mitral valve at relatively low risk, has developed. Two major prospective randomized control trials have been conducted to investigate the clinical advantage of MitraClip system over optimal medical therapy in patients with severe mitral regurgitation; both showed controversial conclusions. Now is a time to consider optimal patient selection and therapeutic strategy using MitraClip system.
本文言語 | 英語 |
---|---|
ページ(範囲) | 636-640 |
ページ数 | 5 |
ジャーナル | International Heart Journal |
巻 | 61 |
号 | 4 |
DOI | |
出版ステータス | 出版済み - 2020 |
ASJC Scopus 主題領域
- 循環器および心血管医学